Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Scientific Reports|July 2, 2025
L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damageHye-Lim Jang, Seung Tae Kim, Jung Yong Hong, et al.
Journal of Korean Medical Science|June 2, 2016
Percentile Distributions of Birth Weight according to Gestational Ages in Korea (2010-2012)Jin Kyoung Lee, Hye Lim Jang, Byung Ho Kang, et al.
Bioscience, Biotechnology, and Biochemistry|February 12, 2019
Orally administered collagen peptide protects against UVB-induced skin aging through the absorption of dipeptide forms, Gly-Pro and Pro-HypHyun-Jun Lee, Hye-Lim Jang, Dong-Kyu Ahn, et al.
Cancer Genetics|July 19, 2025
Prevalence and clinical implications of PIK3CA aberrations across cancer types: A real-world next-generation sequencing approachJunkyu Kim, Hye-Lim Jang, Jung Young Hong, et al.
BMC Cancer|July 21, 2015
Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancerSeung Tae Kim, Kee-Taek Jang, Su Jin Lee, et al.
Pathology, Research and Practice|August 6, 2024
Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysisDae-Ho Choi, Hye-Lim Jang, Sung Hee Lim, et al.
Clinical Endoscopy|September 23, 2024
Development of colonic stent simulator using three-dimensional printing technique: a simulator development study in KoreaHyundam Gu, Suyoung Lee, Sol Kim, et al.
Journal of Korean Medical Science|October 7, 2016
The Experience of Human Milk Banking for 8 Years: Korean PerspectiveHye Lim Jang, Jung Yoon Cho, Mi Jin Kim, et al.
Translational Oncology|March 10, 2015
Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract CancerSeung Tae Kim, Kee-Taek Jang, Jeeyun Lee, et al.
Molecular Cancer Therapeutics|September 25, 2014
Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplificationSeung Tae Kim, Hye-Lim Jang, Su Jin Lee, et al.
Pageof 3